Article Text

other Versions

Download PDFPDF
Predicting the likelihood of lower respiratory tract Ureaplasma infection in preterms
  1. Rose Marie Viscardi1,
  2. Laurence S Magder2,
  3. Michael L Terrin2,
  4. Natalie L Davis1
  1. 1 Department of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland, USA
  2. 2 Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, Maryland, USA
  1. Correspondence to Dr Rose Marie Viscardi, Department of Pediatrics, University of Maryland School of Medicine, Baltimore, MD 21201, USA; rviscard{at}som.umaryland.edu

Abstract

Objective To develop predictive models of Ureaplasma spp lower airway tract infection in preterm infants.

Methods A dataset was assembled from five cohorts of infants born <33 weeks gestational age (GA) enrolled over 17 years (1999–2016) with culture and/or PCR-confirmed tracheal aspirate Ureaplasma status in the first week of life (n=415). Seventeen demographic, obstetric and neonatal factors were analysed including admission white blood cell (WBC) counts. Best subset regression was used to develop three risk scores for lower airway Ureaplasma infection: (1) including admission laboratory values, (2) excluding admission laboratory values and (3) using only data known prenatally.

Results GA and rupture of membranes >72 hours were significant predictors in all 3 models. When all variables including admission laboratory values were included in the regression, WBC count was also predictive in the resulting model. When laboratory values were excluded, delivery route was found to be an additional predictive factor. The area under the curve for the receiver operating characteristic indicated high predictive ability of each model to identify infants with lower airway Ureaplasma infection (range 0.73–0.77).

Conclusion We developed predictive models based on clinical and limited laboratory information available in the perinatal period that can distinguish between low risk (<10%) and high risk (>40%) of lower airway Ureaplasma infection. These may be useful in the design of phase III trials of therapeutic interventions to prevent Ureaplasma-mediated lung disease in preterm infants and in clinical management of at-risk infants.

  • neonatology
  • infectious disease medicine

Data availability statement

Data are available on reasonable request. Data are available on reasonable request by contacting RMV (rviscard@som.umaryland.edu).

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Data availability statement

Data are available on reasonable request. Data are available on reasonable request by contacting RMV (rviscard@som.umaryland.edu).

View Full Text

Footnotes

  • Contributors RMV, MLT, LSM and NLD had full access to all of the data in the study and take responsibility for the integrity of the data and accuracy of the data analysis. RMV is guarantor.

  • Funding This study was funded in part by the National Heart, Blood, and Lung Institute HL71113 and HL087166 and by Eunice Kennedy Shriver National Institute of Child Health and Human Development R01 HD067126.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.